Pediatric Hematology/Oncology

Pharmacology

Questions discussed in this category

When would you consider additional testing for NUDT15 and other polymorphisms related to 6-MP/6-TG metabolism, if not guided by a study protocol?

2 Answers available

Papers discussed in this category

Pharmacogenomics,

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.

Pediatr Blood Cancer, 2011 Feb 22

A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.

Pediatr Blood Cancer, 2011 Jul 27

Pharmacogenetics, cost of genotyping, and guidelines for individualizing therapy with mercaptopurine in pediatric acute lymphoblastic leukemia.

Int J Hematol, 2021 Oct 28

NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China.

Pharmacogenet Genomics,

Cost-effectiveness analysis of pretreatment screening for NUDT15 defective alleles.

Related Topics in Pediatric Hematology/Oncology